Sunshine Biopharma shares fell 5.17% in after-hours trading following the announcement of a one-for-ten reverse stock split effective June 1, 2026. The reverse split aims to meet Nasdaq's minimum bid price requirement by consolidating every ten shares into one, reducing outstanding shares from 21.24 million to about 2.12 million. The company focuses on generic drugs and proprietary treatments in oncology and antiviral fields, with plans to launch new products in 2026. The stock has declined nearly 78% over the past year and currently trades around $0.30 after hours.
VINCI has finalized its acquisition of Fletcher Construction, a major New Zealand company with annual revenue of about €630 million and 2,300 employees. This move strengthens VINCI Construction's position in New Zealand's growing infrastructure marke...
VINCI has finalized its acquisition of Fletcher Construction, a New Zealand company with annual revenue of about 630 million euros and 2,300 employees. This move strengthens VINCI Construction's network in New Zealand, complementing previous acquisit...
Tryg A/S hosted its Analyst Day 2026 on May 28 at its headquarters, focusing on presentations from various business units. The event was aimed at sell-side analysts covering the company's shares. No new financial or strategic targets were revealed du...
Between May 21 and May 27, 2026, Bekaert bought back 51,190 shares at an average price of €41.48, totaling about €2.12 million, as part of its ongoing share buyback program aimed at canceling repurchased shares. Additionally, under its liquidity agre...
Bekaert continued its share buyback program from May 21 to May 27, 2026, purchasing 51,190 shares at an average price of €41.48 per share through Kepler Cheuvreux. The company aims to cancel all repurchased shares, reducing the total outstanding shar...
